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Abstract Matrix metalloproteinase expression is under strict
regulation in physiological conditions. Disruption of the regula-
tory mechanisms can lead to tissue destruction and is associated
with tumour invasion and metastasis. Using the one-hybrid assay
technique with a cis-element in the promoter region of the
stromelysin (matrix metalloproteinase-3) gene, a cDNA encod-
ing a transcription factor termed ZBP-89 was obtained. The
interaction between ZBP-89 and the stromelysin promoter
element was confirmed by electrophoretic mobility shift assays
with a recombinant ZBP-89. Reporter gene expression under the
control of the stromelysin promoter in transiently transfected
cells was significantly increased when the cells were co-
transfected with a ZBP-89 expression construct. These results
indicate that ZBP-89 interacts with the stromelysin promoter
and upregulates its activity. As ZBP-89 expression is known to
be increased in gastric carcinoma cells, induction of stromelysin
expression may be a significant factor in tumour metastasis.
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1. Introduction
The matrix metalloproteinases (MMPs) are a family of zinc-
and calcium-dependent enzymes which degrade a wide range
of structural and adhesive extracellular proteins in neutral pH
environments [1^4]. All members of the MMP family are se-
creted as a latent zymogen and are counteracted by tissue
inhibitors of metalloproteinases (TIMPs). The MMPs play
important roles in various physiological processes involving
resorption and remodelling of extracellular matrix, such as
tissue repair, cell migration, angiogenesis, tissue morphogen-
esis, and growth [1^3,5]. Under physiological conditions, the
expression and activity of MMPs are tightly regulated. This is
accomplished primarily through regulation of gene transcrip-
tion, activation of zymogens and inhibition of proteolytic ac-
tivity by TIMPs [2]. In a number of pathological situations,
however, these regulatory mechanisms become disrupted, re-
sulting in connective tissue destruction or excessive connective
tissue accumulation. For example, over-expression and uncon-
trolled activity of MMPs play a major part in cancer invasion
and metastasis, and are partly responsible for cartilage de-
struction in rheumatoid arthritis ; whereas inadequate MMP
expression and activity are associated with excessive accumu-
lation of connective tissue in systemic sclerosis [1,2,6^8].
According to domain structure and substrate speci¢city, the
MMPs are classi¢ed into four groups, namely the collage-
nases, the gelatinases, the stromelysins and the membrane-
type MMPs [1^4]. Compared with other MMPs, stromely-
sin-1 (MMP3) has the broadest substrate spectrum, possessing
proteolytic activity against collagens III, IV, IX, and X, gel-
atin, proteoglycans, elastin, ¢bronectin, laminin, casein, ag-
grecan, versican, and perlecan. It can also activate a number
of other MMPs including interstitial collagenase, neutrophil
collagenase, collagenase-3, gelatinase B, and matrilysin, there-
fore rendering itself crucial in connective tissue degradation
and remodelling [3].
Regulation of stromelysin expression operates mainly at the
level of transcription. A number of consensus cis-elements in
the promoter region of the stromelysin gene have been shown
to be important in the regulation of stromelysin transcription.
These include a TATA box (330 to 324), an activator pro-
tein-1 (AP-1) site (370 to 364), two polyomavirus enhancer
A binding protein-3 (PEA3) sites (3216 to 3209 and 3208 to
201), a stromelysin PDGF-responsive element (SPRE, 31576
to 31571), and a nerve growth factor-responsive element
(3241 to 3229) [9^12].
In previous work, we found that the sequence between
31626 and 31599 in the stromelysin gene promoter was
also involved in the regulation of transcription [13]. Electro-
phoretic mobility shift assays and DNase I footprinting ex-
periments showed an interaction of this promoter element
with at least one nuclear protein. The identity of the nuclear
protein(s) was, however, obscure. Reported here are results of
our recent study showing interaction of this promoter element
with a transcription factor, ZBP-89, which enhances the ac-
tivity of the stromelysin gene promoter.
2. Materials and methods
2.1. Yeast one-hybrid assay
The MATCHMAKER One-Hybrid System from Clontech was
used in this study. For these assays, the sequence from 31626 to
31599 of the stromelysin gene promoter (5P-AAGACATGG-
TTTTTTCCCCCCATCAAAG-3P) was used as a ‘bait’ to identify
the cDNA for the transcription factor(s) interacting with this pro-
moter sequence. Three concatenated copies of this sequence were li-
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gated into the EcoRI site of the pHISi and pLacZi plasmid vectors
which, respectively, contain a histidine gene and a LacZ gene. The
two resultant plasmid constructs were then sequentially used to trans-
form a yeast strain (YM4271, the endogenous histidine gene in this
yeast strain is inactive due to mutation) to create a dual reporter
strain.
This dual reporter yeast strain was then used to screen a Gal4
activation domain/HeLa cell cDNA library (Clontech). The cDNA
library (with 6U106 independent clones) was ampli¢ed to obtain
3.6U number of independent clones. Dual reporter yeast cells trans-
formed with the cDNA library were cultured on histidine-dropout
medium supplemented with 15 mM 3-aminotriazole. Positive colonies
were then tested for L-galactosidase activity (due to expression of the
‘nocked-in’ LacZ gene) using 5-bromo-4-chloro-3-indolyl-L-D-galacto-
pyranoside as substrate. Plasmid DNA was then prepared from dou-
ble positive colonies (positive both for histidine and LacZ), and used
to transform electrocompetent Escherichia coli DH10B. Plasmid DNA
prepared from the transformed DH10B was sequenced using a com-
mercial cycle sequencing kit (Amersham).
2.2. Rapid ampli¢cation of 3P-cDNA end (3P-RACE)
To clone the 3P-end of the cDNA isolated from the one-hybrid
assay, 3P-RACE was performed using a HeLa cell cDNA library
from Clontech as template. Both ends of library cDNAs had been
ligated with an adapter. Polymerase chain reaction (PCR) was carried
out with the library DNA, a forward primer (5P-CCAGAACA-
GATCGTGTATTGAAACATAAACGTATGTG-3P) corresponding
to the sequence from +792 to +828 relative to the start of translation
of the human ZBP-89 gene, and a reverse primer (5P-CCATCCTAA-
TACGACTCACTATAGGGC-3P) corresponding to part of the li-
brary adapter sequence. Two di¡erent species of PCR products (sized
1.6 kb and 1.8 kb respectively) detected on the agarose gel were
sequenced using a commercial cycle sequencing kit (Amersham).
2.3. In vitro expression of recombinant human ZBP-89
A portion of the human ZBP-89 protein, containing the four zinc
¢nger motifs suggested to be responsible for binding to its cis-element,
was expressed using an in vitro expression system (QIAexpress sys-
tem) from Qiagen. In these experiments, a partial cDNA sequence
from position +180 to +1652 relative to the start of translation of
the human ZBP-89 gene was cloned into the pQE30 vector which
contained six consecutive histidine codons upstream of the multiple
cloning site. Expression of the recombinant protein was performed in
E. coli M15 cells following the manufacturer’s instruction. To increase
the solubility of the recombinant protein, zinc chloride was added to a
¢nal concentration of 1 mM in the culture, the isopropyl-L-thiogalac-
toside concentration was reduced to 0.1 mM and the culture was
incubated for only 1 h at 30‡C. The recombinant protein was puri¢ed
by nickel-nitrilotriacetic acid-agarose resin a⁄nity chromatography
following the manufacturer’s instruction.
2.4. Electrophoretic mobility shift assay
A double-stranded 28-mer oligonucleotide (sequence of top strand:
5P-AAGACATGGTTTTTTCCCCCCATCAAAG-3P) corresponding
to the sequences from 31626 to 31599 in the stromelysin gene pro-
moter was 5P end-labelled with 32P. A 3-Wl aliquot of radiolabelled
probe (3000 cpm/Wl) was mixed with 5 Wl of recombinant human ZBP-
89, 10 Wl 2U binding bu¡er (containing 10 mM Tris-HCl, pH 7.6,
5 mM zinc chloride, 0.5 mM dithiothreitol, 10% glycerol), 1 Wl 500 ng/Wl
poly(dI-dC), and 1 Wl of unlabelled oligonucleotide (speci¢c or non-
speci¢c competitors). The mixture was incubated at room temperature
for 20 min, and fractionated on a 7% non-denaturing polyacrylamide
gel (acrylamide:bisacrylamide = 80:1) in 0.25UTBE bu¡er for 2 h at
200 V, room temperature. The gel was then dried and exposed to
Hyper¢lm-MP (Amersham) at room temperature without intensifying
screen for 72 h.
2.5. Transfection experiments
Constructs used in these experiments were as follows: (1) pCI-
ZBP89 which was prepared by cloning the full-length cDNA for
ZBP-89 into a mammalian expression vector (pCI vector, Promega);
(2) pGL-Str which was prepared by subcloning the stromelysin pro-
moter from a previously reported chloramphenicol acetyltransferase
reporter gene construct [13] into a ¢re£y luciferase reporter vector
(pGL3-basic vector, Promega); (3) pRL-TK (Promega) which ex-
presses renilla luciferase by a thymidine kinase promoter and was
used as a control for transfection e⁄ciency.
Using the lipofection method as described previously [13], cultured
rat smooth muscle cells (A10) were transiently transfected with 2.5 Wg
of pGL-Str, 0.4 Wg of pRL-TK, and various amounts (2.5, 5 or 10 Wg)
of either pCI-ZBP89 or the pCI vector without the ZBP89 insert.
Twenty-four hours after transfection, luciferase activities were meas-
ured using a commercial dual-luciferase assay system (Promega). Lu-
ciferase levels were denoted by the ratio of ¢re£y luciferase activity
over renilla luciferase activity.
3. Results
3.1. Identi¢cation of a cDNA encoding a transcription factor
interacting with the stromelysin promoter
Our previous studies indicated that the sequence from
31626 to 31599 of the stromelysin gene promoter was recog-
nised by at least one nuclear factor and involved in transcrip-
tion regulation. In the present study, a yeast one-hybrid assay
technique (see Section 2) was utilised to identify the nuclear
factors. In these experiments, three concatenated copies of the
promoter element (31626 to 31599 relative to the start of
transcription of the stromelysin gene) were used as a ‘bait’
to screen 6U106 independent clones of a HeLa cell cDNA
library. As a result, a total of 19 highly positive colonies
were obtained. Restriction enzyme digestion and DNA se-
quencing analyses revealed that all 19 clones contained the
same partial cDNA sequence (approximately 1 kb) identical
to a portion of the gene encoding a transcription factor cloned
Fig. 1. Rapid ampli¢cation of 3P-cDNA end (3P-RACE) of ZBP-89.
PCR templates were a HeLa cell cDNA library that had been li-
gated with an adapter. Lane 1, DNA size marker; lane 2, products
of PCR with an oligonucleotide corresponding to part of the adapt-
er sequence; lane 3, PCR amplicons from a primer as used in the
PCR in lane 2 and a primer corresponding to the sequence from
+792 to +828 relative to the start of translation of the human ZBP-
89 cDNA.
FEBS 21971 4-5-99
S. Ye et al./FEBS Letters 450 (1999) 268^272 269
by Wang et al. [14] and Law et al. [15], which was named htL
and ZBP-89 respectively. The partial cDNA sequence ob-
tained in these experiments contained the coding sequence
for the four zinc ¢nger motifs of this transcription factor
which were suggested to form the DNA binding domain of
this transcription factor.
Multiple sequence alignment revealed 100% identity among
the approximately 1-kb sequence obtained in these experi-
ments and the corresponding region (+238 to +1164 relative
to the start of transcription) of the sequences by Wang et al.
(htL, accession number L04282) and by Law et al. (ZBP-89,
accession number AF039019) respectively. However, 3P to this
region, there were a number of discrepancies (substitutions
and deletions) between the sequence by Wang et al. and
that by Law et al., and the predicted protein by Law et al.
was longer than that predicted by Wang et al. To further
characterise the 3P portion of this gene, 3P-RACE (see Section
2) was carried out, using a cDNA library as template, a PCR
primer corresponding to the sequence from +792 to +828
relative to the start of translation, and a second primer cor-
responding to the sequence of an adapter that had been li-
gated to the cDNA library. Two di¡erent PCR products, sized
1.6 kb and 1.8 kb, were obtained (Fig. 1). DNA sequencing
revealed that the 1.6-kb amplicon corresponded to a sequence
from the position of the internal PCR primer to the ¢rst stop
codon, whereas the 1.8-kb amplicon also began from the in-
ternal PCR primer but extended to a position approximately
200 bp beyond the ¢rst stop codon. Our sequence (accession
number AJ236885) shared 99% similarity with the sequence by
Law et al. (AF039019). The discrepancies between our se-
quence and that of Law et al. are shown in Table 1.
3.2. Characterisation of the DNA element in the stromelysin
gene promoter interacting with ZBP-89
Electrophoretic mobility shift assays were carried out to
con¢rm the interaction between ZBP-89 and the 31626 to
31599 sequence in the stromelysin gene promoter. A puri¢ed
recombinant protein containing the four zinc ¢nger motifs
(the DNA binding domain) of ZBP-89 was incubated with a
32P-labelled double-stranded oligonucleotide probe (5P-AA-
GACATGGTTTTTTCCCCCCATCAAAG-3P) correspond-
ing to the 31626 to 31599 sequence in the stromelysin gene
promoter, followed by polyacrylamide gel electrophoresis. As
shown in Fig. 2, a DNA-protein complex was detected (lane
2), and the DNA-protein interaction was zinc-dependent (lane
9). The signal of the DNA-protein complex was signi¢cantly
reduced in the presence of unlabelled double-stranded wild-
type oligonucleotide (lane 3) and mutant oligonucleotides with
a change of one or two bases outside the GC box (M1, lane 4;
and M2, lane 5). The signal was also slightly reduced in the
presence of a mutant oligonucleotide with a change of eight
bases next to the GC box (M4, lane 7), but the reduction in
band intensity was less pronounced as compared with the
assays in lanes 3, 4 and 5. An oligonucleotide competitor
with a mutation in the GC box did not decrease the signal
of the DNA-protein complex (M3, lane 6), nor did a non-
speci¢c competitor (lane 8).
3.3. ZBP-89 enhances stromelysin gene promoter activity
Transient transfection experiments were carried out to de-
termine whether ZBP-89 had an e¡ect on stromelysin pro-
moter activity. For these experiments, a full-length ZBP-89
Fig. 2. ZBP-89 interacts with the sequence from 31626 to 31599 in
the stromelysin gene promoter. Electrophoretic mobility shift assays
were carried out using a 32P-labelled double-stranded oligonucleo-
tide probe corresponding to the sequence from 31626 to 31599 in
the stromelysin gene promoter (AAGACATGGTTTTTTCCCCC-
CATCAAAG). Lane 1, 32P-labelled probe alone; lane 2, 32P-la-
belled probe incubated with recombinant ZBP-89 in the absence of
competitors. Lanes 3^8, 32P-labelled probe incubated with recombi-
nant ZBP-89 in the presence of various competitors (100-fold ex-
cess), i.e. lane 3, AAGACATGGTTTTTTCCCCCCATCAAAG (un-
labeled probe); lane 4, AAGACATGGTTTTTCCCCCCATCAAAG
(M1); lane 5, AAGACATGGTTGGTTCCCCCCATCAAAG (M2);
lane 6, AAGACATGGTTTTTTCCTTCCATCAAAG (M3); lane 7,
AAGACATCTAAGTATCCCCCCATCAAAG (M4); lane 8, non-
speci¢c competitor. Lane 9, ZnCl2 omitted in the reaction bu¡er;
lane 10, probe incubated with lysates from pCI-ZBP89-transformed
E. coli uninduced with isopropyl-L-D-thiogalactoside.
Table 1
Comparison of the ZBP-89 cDNA cloned in this study with that by Law et al. [15]
cDNA Nucleotide position
1042 1438 1749 2127 2401 2449
Ye et al. ctGttta taCGttc ccccAtc aagtCac gtg.aaa actAtgt
Val Arg Pro Val 3P UTR 3P UTR
Law et al. ctCttta taGCttc ccccGtc aagtGac gtgTaaa actCtgt
Leu Ala Pro Val 3P UTR 3P UTR
Nucleotide positions are denoted in relation to the ¢rst ATG codon. Nucleotides that are di¡erent between the two sequences are shown in
upper case.
GenBank accession numbers: Ye et al., AJ236885; Law et al., AF039019.
FEBS 21971 4-5-99
S. Ye et al./FEBS Letters 450 (1999) 268^272270
cDNA was cloned in a mammalian expression vector (pCI-
vector). The resultant ZBP-89 expression construct (pZBP89-
CI), together with a construct (pGL-Str) containing the stro-
melysin gene promoter linked to a ¢re£y luciferase reporter
gene, were co-transfected into cultured A10 cells. A plasmid
(pRL-TK) expressing renilla luciferase under the control of
the thymidine kinase promoter was also co-transfected to pro-
vide a reference for transfection e⁄ciency. The level of ¢re£y
luciferase (after standardisation against renilla luciferase) in
these transfectants was compared with the level of ¢re£y lu-
ciferase (also standardised against renilla luciferase) in A10
cells transfected with pCI-vector (lacking the ZBP-89 insert),
pGL-Str and pRL-TK. As shown in Fig. 3, ¢re£y luciferase
levels in cells co-transfected with the ZBP-89 expression con-
struct were higher than those in cells co-transfected with the
pCI-vector lacking the ZBP-89 insert, suggesting that ZBP-89
enhanced the activity of the stromelysin gene promoter. There
also appeared to be a dose e¡ect: a three-fold di¡erence in
standardised ¢re£y luciferase was observed when comparing
cells co-transfected with 2.5 Wg of pZBP89-CI to cells co-
transfected with the equivalent amount of pCI-vector; the
di¡erence increased to ¢ve-fold for cells transfected with 5 Wg
of either plasmid and 6.5-fold for cells transfected with 10 Wg
of plasmid.
4. Discussion
Expression of stromelysin is regulated by a variety of cyto-
kines, growth factors, and hormones. For example, its expres-
sion is induced by epidermal growth factor (EGF), platelet-
derived growth factor (PDGF), nerve growth factor (NGF),
interleukin-1 (IL-1) and tumour promoters, but inhibited by
transforming growth factor and glucocorticoid [10,12,16^20].
The e¡ects of these regulatory agents on stromelysin expres-
sion largely operate at the level of transcription involving a
number of cis-elements in the promoter region of the strome-
lysin gene. Substantial research has been undertaken into the
role of the AP-1 site (370 to 364) which is bound by tran-
scription factors c-Fos and c-Jun, and the PEA3 elements
(3215 to 3201) recognised by transcription factor Ets [16^
19,21]. These cis-elements and trans-factors have been found
to be essential for the steady-state expression of stromelysin
and for the response to various growth factors and cytokines
such as EGF and IL-1 as well as tumour promoters such as
phorbol esters [11,18,20,22]. In addition, a cis-element (termed
SPRE) located further upstream (31576 to 31571), which
interacts with a transcription factor containing a leucine zip-
per region, has been reported to be involved in the response to
PDGF stimulation [23,24], and an element (3241 to 3229)
bound by another member of leucine zipper gene family is
involved in NGF induction [25].
Previously we showed that the sequence from 31626 to
31599 relative to the start of transcription was also involved
in the regulation of stromelysin promoter activity. Interaction
of nuclear factors with this promoter element was demon-
strated by electrophoretic mobility shift assays and DNase I
footprinting experiments. The identity of the nuclear factors
binding to this region of the stromelysin gene promoter was,
however, obscure. The data reported here indicate that tran-
scription factor ZBP-89 interacts with this promoter element.
Results of the transfection experiments also suggest that ZBP-
89 enhances stromelysin gene promoter activity.
Transcription factor ZBP-89 has been shown to interact
with promoter sequences containing a GC box in a number
of di¡erent genes, including those in the genes encoding hu-
man T-cell receptor VL8.1 (CACCACCCCCAACTTC) [14],
mouse T-cell receptor K silencer I (CACCCCACCCC-
CACCC) [14], human gastrin (CCCCCCACCCCGCCCC)
[26], mouse type I collagen K2 (I) (TCCCTCCCCCCTCGGC)
[27], mouse type I collagen K1 (I) (TCCTCCCCCCTCTT and
GCGCCCCCCCTCCCGC) [27] and human ornithine decar-
boxylase (GCCCCTCCCCC) [15]. The results of this study
indicate that it also interacts with the GC box within the
sequence from 31626 to 31599 (GGTTTTTTCCCCCCAT-
CAAA) in the stromelysin gene.
The e¡ect of ZBP-89 on gene regulation appears to be
dependent on the context of the relevant promoter. For ex-
ample, it activates the human T-cell receptor gene promoter
[14], but is repressive for the promoters of the human gastrin
and ornithine decarboxylase genes [15,28]. In all these cases,
regardless of whether it acts as an enhancer or repressor,
ZBP-89 appears to compete with another transcription factor
for binding to the promoter element. Where it competes with
a transcription activator such as in the case of the gastrin [26]
and ornithine decarboxylase [15] genes, ZBP-89 exerts a re-
pressive e¡ect. In contrast, where the competitor of ZBP-89 is
a transcription silencer such as in the case of the T-cell recep-
tor gene [14], ZBP-89 has an upregulatory e¡ect.
Using a ZBP-89 cDNA probe, we have carried out North-
ern blot analyses with mRNA from various tissues including
heart, brain, lung, liver, kidney, pancreas, skeletal muscle and
placenta. Two RNA species, with estimated sizes of 4.1 kb
and 7.5 kb respectively, were detected, which is consistent
with the ¢ndings of Wang et al. [14]. Both transcripts were
detectable in all tissues examined, indicating that ZBP-89 is an
ubiquitous transcription factor. It is interesting that expres-
sion of ZBP-89 has been shown to be increased in gastric
cancer tissues [29]. It is therefore plausible that in addition
to other possible consequences, overexpression of ZBP-89 in
neoplastic cells might lead to increased expression of strome-
lysin as the data reported here suggest that ZBP-89 enhances
stromelysin gene promoter activity. If this is the case, upregu-
Fig. 3. ZBP-89 enhances stromelysin promoter activity. Transient
transfection was performed on A10 cells. Open bars represent cells
transfected with 2.5 Wg of pGL-Str, 0.4 Wg of pRL-TK, and various
amount of pCI-vector as indicated. Closed bars represent cells trans-
fected with 2.5 Wg of pGL-Str, 0.4 Wg of pRL-TK, and various
amount of pCI-ZBP89 as indicated. Each transfection was done in
duplicate. Data shown (mean+S.D.) are the ratios of ¢re£y lucifer-
ase activity versus renilla luciferase activity using a dual-luciferase
reporter assay system with each assay carried out in duplicate.
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lation of stromelysin expression by ZBP-89 may be an impor-
tant mechanism conferring cancer cells with the ability to
invade and metastasise. Further studies are required to exam-
ine this possibility.
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